

Risk of ovarian function recovery should be considered with adjuvant tamoxifen to aromatase inhibitor therapy chemotherapy-induced amenorrhea

Ca-A Cancer Journal for Clinicians

68, 5-6

DOI: [10.3322/caac.21415](https://doi.org/10.3322/caac.21415)

Citation Report

| # | ARTICLE   | IF  | CITATIONS |
|---|---|-----|-----------|
| 1 | Identification of biomarkers and drug repurposing candidates based on an immune-, inflammation- and membranous glomerulonephritis-associated triplets network for membranous glomerulonephritis. BMC Medical Genomics, 2020, 13, 5.   | 0.7 | 6         |
| 2 | Tactics for minimizing risk of increasing estradiol against the background of aromatase inhibitors in combination with gonadotropin releasing hormone agonists in adjuvant therapy for breast cancer in premenopausal patients. Pilot study results. Meditsinskiy Sovet, 2018, , 76-84. | 0.1 | 0         |